Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Merck
Express Scripts
Colorcon
Dow

Last Updated: May 21, 2022

CLINICAL TRIALS PROFILE FOR SOMATULINE DEPOT


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Somatuline Depot

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00149188 ↗ Somatuline Autogel: Acromegaly Self/Partner Injection Study Completed Ipsen Phase 4 2004-02-01 The purpose of this study is to allow patients with acromegaly, or their partners, to learn how to successfully inject Somatuline Autogel at home. Ability to perform unsupervised injections whilst maintaining adequate disease control will be assessed.
NCT00216398 ↗ Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR Completed Ipsen Phase 4 2004-06-01 The purpose of this study is to assess the efficacy, safety and patient acceptability of Somatuline Autogel in patients with acromegaly previously treated with octreotide LAR.
NCT00288522 ↗ Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment Terminated Ipsen Phase 2 2006-01-01 The main purpose of this study is to evaluate the efficacy and safety of 3 doses of Somatuline Autogel 60mg to control the muscle infiltration and edema, eyelid retraction and extraocular muscular contraction in patients with active thyroid-associated ophthalmopathy of moderate intensity.
NCT00444873 ↗ Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly Completed Ipsen Phase 3 2005-01-01 A multicentre, prospective, open label study of acromegalic patients evaluating the efficacy and safety of different dose-intervals of Lanreotide Autogel 120mg according to international standards and compared to previous treatment with Octreotide LAR 10, 20 or 30 mg.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Somatuline Depot

Condition Name

Condition Name for Somatuline Depot
Intervention Trials
Acromegaly 9
Neuroendocrine Tumors 2
Neuroendocrine Tumours 2
Carcinoid Tumors 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Somatuline Depot
Intervention Trials
Acromegaly 9
Carcinoid Tumor 7
Neuroendocrine Tumors 7
Carcinoma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Somatuline Depot

Trials by Country

Trials by Country for Somatuline Depot
Location Trials
United States 44
United Kingdom 6
Canada 5
Australia 4
Belgium 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Somatuline Depot
Location Trials
California 6
New York 3
Maryland 3
Colorado 3
Oregon 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Somatuline Depot

Clinical Trial Phase

Clinical Trial Phase for Somatuline Depot
Clinical Trial Phase Trials
Phase 4 5
Phase 3 8
Phase 2 8
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Somatuline Depot
Clinical Trial Phase Trials
Completed 13
Terminated 4
Unknown status 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Somatuline Depot

Sponsor Name

Sponsor Name for Somatuline Depot
Sponsor Trials
Ipsen 19
Radboud University 2
Cedars-Sinai Medical Center 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Somatuline Depot
Sponsor Trials
Other 24
Industry 19
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Dow
Medtronic
Merck
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.